5 completed, 2 terminated. 4 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Progen Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma PI-88, placebo - Cancer, Liver Cancer | Phase 3 | Terminated | Progen Pharmaceuticals | 600 | 2007-12-01 | 2011-06-15 |
| Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD CGC-11047 - Age Related Macular Degeneration | Phase 1 | Completed | Progen Pharmaceuticals | 43 | 2007-04-01 | 2012-08-06 |
| Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer CGC-11047 - Prostate Cancer | Phase 2 | Terminated | University of Wisconsin, Madison | 23 | 2006-06-01 | 2015-10-02 |
| Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab - Cancer | Phase 1 | Completed | Progen Pharmaceuticals | 172 | 2006-05-01 | 2016-07-21 |
| SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma polyamine analogue PG11047 - Lymphoma | Phase 1 | Completed | Progen Pharmaceuticals | 20 | 2006-01-01 | 2016-06-23 |
| Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer PI-88, docetaxel, prednisone - Prostate Cancer | Phase 2 | Completed | Progen Pharmaceuticals | 48 | 2005-08-01 | 2011-06-15 |
| Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors PG-11047 - Cancer | Phase 1 | Completed | Progen Pharmaceuticals | 46 | 2005-03-01 | 2012-03-27 |
Neoplasms (3) · Lymphoma (2) · Prostatic Neoplasms (2) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Liver Neoplasms (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Macular Degeneration (1)
(N(1),N(12))bis(ethyl)-6,7-dehydrospermine (3) · CGC 11047 (3) · Docetaxel (2) · phosphomannopentaose sulfate (2) · Bevacizumab (1) · Cisplatin (1) · Erlotinib Hydrochloride (1) · Fluorouracil (1) · Gemcitabine (1) · Leucovorin (1) · Prednisone (1) · Sunitinib (1)
United States (6) · Australia (2) · Canada (1) · Hong Kong (1) · Italy (1) · Malaysia (1) · Mexico (1) · Russia (1) · Singapore (1) · Spain (1) · Taiwan (1) · Thailand (1)
Barbara Hicks (1) · Gavin Marx, MD (1) · Joe Stephenson, MD (1) · Mark Ratain, M.D. (1) · Nick Pavlakis, MD (1) · Peter Campochiaro, MD (1) · Ronnie TP Poon, MD (1)